Masteron Propionate 100 mg/ml (UP)

UNIQUE PHARMA QUALITY: Premium pharmaceutical grade Drostanolone Propionate (Masteron Propionate) manufactured under strict GMP conditions with 99.8% purity verification.

Masteron Propionate from Unique Pharma represents our commitment to delivering exceptional quality performance enhancement compounds. Each batch undergoes rigorous testing to ensure consistent potency and purity standards.

Key Characteristics of Masteron Propionate

This injectable compound is administered via intramuscular injection and remains active in your system for approximately 2-3 Days. Notable features include:

• Pharmaceutical grade manufacturing
• Batch-tested for purity and potency
• Consistent dosing per unit
• Optimal bioavailability

Primary Benefits:

• Enhanced performance and recovery
• Quality-assured formulation
• Reliable and consistent results
• Professional-grade compound

Mechanism of Action

Drostanolone Propionate works by interacting with androgen receptors in muscle tissue, promoting protein synthesis and nitrogen retention. This creates an optimal environment for muscle development and recovery. The compound's unique molecular structure provides specific benefits that distinguish it from other options in its class.

Usage Guidelines

Unique Pharma Masteron Propionate is suitable for experienced users who understand proper cycling protocols. Always consult with a healthcare professional before beginning any supplementation regimen. Proper post-cycle therapy should be considered based on individual needs and cycle duration.

Recommended Applications

This compound is commonly incorporated into both bulking and cutting protocols depending on the user's specific goals. Its versatility makes it a popular choice among athletes and bodybuilders seeking reliable results.

Potential Considerations

As with any performance compound, users should be aware of potential effects and monitor their response accordingly. Regular health monitoring is recommended during use. Individual responses may vary based on genetics, diet, training, and other factors.

Quality Assurance

Every Unique Pharma product undergoes comprehensive quality control including:

• Raw material verification
• In-process testing
• Final product analysis
• Stability testing

Warning: Keep out of reach of children. For adults only. Not intended for use by individuals under 18 years of age.

Related products

Other Unique Pharma products

• Test E 250
• Deca 200
• Tren A 100
• Mast E 200

1. Description — Clinical summary

“Mast P 100 mg/mL” refers to drostanolone propionate (commonly known by the trade name Masteron) formulated at 100 mg per milliliter for intramuscular injection. Drostanolone is a synthetic androgen derived from dihydrotestosterone (DHT). Historically it was used in oncology (primarily for certain cases of breast cancer) and in some countries was available by prescription for androgen-responsive conditions; contemporary legitimate medical use is limited and largely historical. Outside clinical settings it has been used illicitly for anabolic/androgenic purposes (e.g., physique and performance enhancement), which carries medical and legal risks.

Use of drostanolone should be by prescription and under specialist supervision. The information below is educational and not an endorsement of non‑prescribed use.

2. How does masteron‑propionate work? — Mechanism of action

• Drostanolone is a DHT derivative and a potent agonist of the androgen receptor (AR). When administered, it binds ARs in muscle, bone, and other tissues to produce androgenic and anabolic effects:
  • Increases protein synthesis and nitrogen retention, which can support maintenance or increase of lean tissue.
  • Reduces catabolism and can promote muscular hardness/definition due to its low water‑retaining properties.
• The 2α‑methyl modification increases resistance to metabolic breakdown and alters receptor interactions; the propionate ester is short‑acting, producing a relatively rapid onset and short duration after intramuscular injection.
• Importantly, drostanolone does not aromatize to estrogen (it is not converted by aromatase). As a result, estrogen‑mediated effects such as gynecomastia or fluid retention are uncommon. However, the androgenic activity produces its own spectrum of adverse effects.
• Systemic androgen exposure suppresses the hypothalamic–pituitary–gonadal (HPG) axis, reducing endogenous testosterone production and spermatogenesis.

3. Dosage — Medical and varying usage guidelines

Important: approved, evidence‑based medical dosing for drostanolone propionate is limited in contemporary practice. Any therapeutic use should be supervised by a qualified clinician. The following describes historical/reported regimens and observed non‑medical use; it is provided for educational context only.

• Medical (historical/oncologic):

  • Drostanolone was previously used in certain androgen‑responsive breast cancers. Dosing in older literature was individualized; some historic regimens reported injections on the order of tens to a few hundred milligrams per week divided into multiple doses. Contemporary oncologic practice typically favors other systemic therapies, and drostanolone is rarely used today.
  • If considered medically, a specialist (e.g., oncologist or endocrinologist) determines dose, frequency, duration, monitoring, and eligibility.

• Off‑label/non‑medical reports (frequently encountered in bodybuilding literature; not recommended and associated with health risks):

  • Because drostanolone propionate has a short ester, injected schedules reported in non‑medical sources commonly use injections every other day or several times per week to maintain relatively stable blood levels.
  • Reported ranges (non‑medical reports only): 50–150 mg per injection, given every other day or 2–3 times per week; total weekly amounts commonly reported around 150–400 mg. These are not medical recommendations.
  • Women in non‑medical settings report much lower doses when they use androgenic agents (e.g., single low doses given infrequently) because virilization risk is high even at modest doses. Any use by women carries a significant risk of irreversible virilizing effects.

• Duration:

  • Medical course and duration are condition‑dependent. Non‑medical cycles commonly last 6–12 weeks, but longer exposure increases risk of adverse effects, including prolonged HPG axis suppression.

• Peri‑treatment considerations:

  • Baseline assessment (cardiovascular risk factors, lipids, liver and kidney function, hematology, testosterone/sex hormone levels, PSA in men) and periodic monitoring during treatment.
  • Expect suppression of endogenous testosterone; post‑treatment recovery planning (e.g., endocrine follow‑up) is necessary if systemic androgen therapy is stopped.

Because authorized medical indications and dosing are limited and regionally variable, a prescriber’s guidance is essential.

4. Side effects — Common and rare adverse effects

Adverse effects arise from drostanolone’s androgenic activity, metabolic effects, and from injectable administration. Severity depends on dose, duration, sex, age, comorbidities, and concomitant drugs.

Common/likely

• Androgenic effects
  • Acne, oily skin
  • Increased facial/body hair or acceleration of male pattern baldness in genetically susceptible men
  • Virilization in women: deepening of the voice, clitoral enlargement, menstrual irregularities, hirsutism — some effects can be irreversible
• Endocrine suppression
  • Suppression of the HPG axis → reduced endogenous testosterone, testicular atrophy, decreased sperm production and fertility (may persist for varying periods after cessation)
• Lipid and metabolic changes
  • Reduced HDL cholesterol, increased LDL cholesterol → adverse cardiovascular risk profile
• Hematologic
  • Erythrocytosis/polycythemia (elevated hematocrit and hemoglobin) → increased thrombotic risk
• Injection‑related
  • Injection site pain, local inflammation, infection if aseptic technique not used

Less common/serious (rare but important)

• Cardiovascular events
  • Increased risk of hypertension, accelerated atherosclerosis, myocardial infarction, stroke — especially with long‑term abuse or in persons with preexisting cardiovascular disease
• Psychiatric/behavioral
  • Mood swings, irritability, aggression, depression, changes in libido
• Hepatic effects
  • Drostanolone is not a 17‑alkylated oral steroid and therefore has a lower risk of hepatotoxicity than many oral AAS; nevertheless abnormal liver tests have been reported with use of anabolic agents and should be monitored
• Allergic reactions
  • Hypersensitivity to drug or excipients (rash, anaphylaxis — rare)
• Prostate effects (men)
  • Potential to exacerbate benign prostatic hyperplasia (BPH) and to affect prostate cancer biology; PSA monitoring recommended if used in men

Contraindications

• Pregnancy and breastfeeding (androgens cause virilization of a female fetus)
• Known hypersensitivity to drostanolone or formulation components
• Uncontrolled cardiovascular disease, severe dyslipidemia, active prostate cancer (men), and certain other endocrine disorders as determined by a clinician

Drug interactions

• May alter effects of oral anticoagulants (monitor INR)
• Additive effects with other androgens or anabolic agents
• Can affect glycemic control — caution with insulin or antidiabetic drugs
• Concomitant use with drugs that adversely affect lipids or cardiovascular risk should be carefully considered

5. Storage — How to store it

• Store the sealed vial at controlled room temperature, typically 20–25 °C (68–77 °F), unless the product labeling specifies otherwise. Short excursions (e.g., 15–30 °C / 59–86 °F) are generally acceptable, but follow the product leaflet.
• Protect from light and excessive heat. Do not freeze.
• Keep vial in its original carton to protect from light.
• Keep out of reach of children and unauthorized persons.
• Do not use if the solution is cloudy, discolored, or contains particulates (unless the prescribing information states otherwise) — dispose of single‑use products after opening per local regulations.
• Dispose of needles, syringes, and unused medication safely following local biomedical waste guidance.

Important final notes

• Drostanolone propionate is a prescription medication (or controlled substance in many jurisdictions). Use without medical indication or prescription can be illegal and medically hazardous.
• If drostanolone is being considered for any medical indication, treatment should be managed by an experienced clinician with appropriate baseline evaluation and ongoing monitoring (lipids, CBC, liver/renal function, blood pressure, PSA as indicated, endocrine tests).
• If you or someone is experiencing adverse effects (e.g., chest pain, severe shortness of breath, signs of blood clot, severe mood changes, signs of liver dysfunction, allergic reaction), seek immediate medical attention.

If you’d like, I can provide references to primary literature and clinical reviews, or a checklist of baseline and follow‑up investigations clinicians commonly use when monitoring androgen therapy.

1. Description — Clinical summary

Mast P 100 mg/ml (active compound: drostanolone propionate, commonly called “masteron‑propionate”) is an injectable anabolic androgenic steroid (AAS). Drostanolone is a 2α‑methyl derivative of dihydrotestosterone (DHT). It was developed and used historically in oncology (principally for some forms of breast cancer) but is not widely used in contemporary mainstream medicine. It is most commonly encountered today in non‑medical settings (e.g., sport/bodybuilding) as an anabolic agent.

Pharmacologically, drostanolone is a potent androgen receptor agonist with weak or absent aromatization to estrogens. The propionate ester confers a relatively short intramuscular half‑life (on the order of ~2–3 days), so dosing is typically multiple times per week when used clinically or experimentally.

This guide is educational and not a substitute for medical advice. Use under medical supervision is required; the compound is regulated/controlled in many jurisdictions.

2. How does masteron‑propionate work? — Mechanism of action

• Androgen receptor (AR) agonism: drostanolone binds the AR with high affinity, producing typical androgenic/anabolic effects — increased protein synthesis, nitrogen retention, and stimulation of muscle growth and strength.
• DHT derivative: being a DHT analog (2α‑methyl‑DHT) it is not a substrate for aromatase and therefore does not convert to estrogen. This minimizes estrogen‑mediated effects such as water retention and gynecomastia.
• Tissue effects: strong androgenic effects in muscle and other androgen‑sensitive tissues; in breast tissue drostanolone historically produced anti‑tumor effects in some estrogen‑sensitive breast cancers—likely through androgen receptor–mediated antagonism of estrogen signaling and lack of aromatization.
• Secondary effects: suppression of the hypothalamic–pituitary–gonadal (HPG) axis (decreased LH/FSH and endogenous testosterone production) with sustained use. It can also affect lipid metabolism (typically decreasing HDL and increasing LDL) and erythropoiesis (increasing hematocrit).

Note: Some reported “anti‑estrogenic” effects are indirect (non‑aromatizable and AR‑mediated) rather than via direct aromatase inhibition; the exact contributions can vary and are incompletely defined.

3. Dosage — Medical and usage guidelines

Important: drostanolone propionate is not broadly approved for routine indications (e.g., testosterone deficiency). Dosing below reflects historical clinical practice and commonly reported regimens; any use should be under specialist supervision with informed consent and appropriate monitoring.

Pharmacokinetics: propionate ester = shorter half‑life (~2–3 days). Typical injection frequency for stable levels is every other day or every 2–3 days.

Medical/historical dosing

• Oncology (historic; women with advanced breast cancer): published regimens commonly used 100 mg intramuscular (IM) two to three times per week (≈200–300 mg/week). These were supervised, therapeutic regimens in oncology settings.
• Approved contemporary indications: none widely used; check local product labeling and regulatory approval.

Commonly reported (non‑medical / performance) dosing patterns — for context only

• Men: typical anecdotal ranges 200–400 mg/week (divided injections every 2–3 days). Some users report up to 400–600 mg/week, but higher doses increase adverse effects and are not medically recommended.
• Women: much lower doses to reduce virilization risk — commonly 50–100 mg/week (divided). Even at low doses, women are at high risk of virilizing effects; many clinicians advise avoiding use in women unless absolutely indicated and closely monitored.

Special populations

• Adolescents: contraindicated except under rare specialist guidance (risk of premature epiphyseal closure and virilization).
• Pregnancy/Breastfeeding: contraindicated (risk of fetal virilization).

Dose adjustment and duration

• Use the lowest effective dose for the shortest necessary duration.
• Treatment duration and need for intervening breaks or post‑treatment recovery should be determined by a treating physician.
• Because drostanolone suppresses endogenous testosterone, prolonged courses often require recovery strategies (medical evaluation; post‑therapy hormonal management under clinician guidance).

Monitoring recommendations (baseline and during therapy)

• Baseline: CBC (hematocrit/hemoglobin), fasting lipids, liver function tests (LFTs), renal function, fasting glucose/HbA1c (if diabetic risk), testosterone, LH/FSH, PSA (men), pregnancy test (women).
• Follow‑up: CBC and lipids every 4–12 weeks during active therapy; LFTs and testosterone periodically; PSA as clinically indicated in men; blood pressure monitoring.

4. Side effects — Common and serious adverse effects

Common / dose‑related and usually reversible (with cessation)

• Suppression of HPG axis → decreased endogenous testosterone, infertility, testicular atrophy.
• Acne and oily skin.
• Hair loss (accelerates male pattern baldness in genetically predisposed men).
• Changes in libido (increase or decrease).
• Injection‑site pain, irritation, or local reactions.
• Adverse lipid effects: decreased HDL, increased LDL — can accelerate atherosclerotic risk.
• Increased hematocrit/polycythemia → increased blood viscosity and thrombotic risk.

Virilizing and irreversible effects (especially in women; may be partially irreversible)

• Deepening of voice (may be irreversible).
• Hirsutism (increased facial/body hair).
• Menstrual disturbances and clitoromegaly.
• Masculinization of a female fetus if exposure occurs during pregnancy — absolute contraindication in pregnancy.

Less common / serious

• Cardiovascular events: hypertension, accelerated atherosclerosis, myocardial infarction risk increased with dyslipidemia and other risk factors.
• Prostatic effects in older men: benign prostatic hyperplasia (BPH) exacerbation, possible effect on prostate cancer risk; monitor PSA.
• Polycythemia with thrombotic complications (stroke, pulmonary embolism) if Hct becomes markedly elevated.
• Rare hypersensitivity/allergic reactions.
• Liver toxicity: injectable drostanolone (non‑17α‑alkylated) has a much lower risk of clinically significant hepatotoxicity than 17‑alkylated oral AAS, but monitoring of LFTs is still prudent.
• Psychiatric effects: mood changes, aggression, irritability, depression on withdrawal.

Drug interactions / important cautions

• Anticoagulants (e.g., warfarin): AAS can potentiate or unpredictably alter anticoagulant response — monitor INR closely.
• Concurrent use with other androgens/anabolic steroids or contraindicated medications increases adverse event risk.
• Care with insulin and antidiabetic agents because androgens can alter glucose metabolism.

Management of adverse effects (general guidance)

• Mild side effects: consider dose reduction and close monitoring.
• Significant erythrocytosis: consider therapeutic phlebotomy and stop or reduce androgen therapy.
• Lipid abnormalities: lifestyle modification; consider lipid‑lowering therapy as indicated.
• Testosterone suppression: evaluate and manage under endocrinology/urology; post‑therapy recovery may be slow and sometimes requires medical intervention.
• Virilization in women: prompt discontinuation is recommended to limit progression; some changes (e.g., voice deepening) may be permanent.

5. Storage — How to store it

• Store at controlled room temperature, typically 15–25°C (59–77°F). Avoid extremes of heat and cold; do not freeze.
• Protect from direct sunlight and store in original container.
• Keep container tightly closed and in a clean, dry place.
• Do not use if the solution is discolored, cloudy (when it should be clear), contains particulate matter, or if the vial seal is compromised.
• Single‑use vs multi‑dose: follow the manufacturer’s labeling. If multi‑dose and preservative present, follow aseptic technique; discard according to local guidelines and expiration times after opening.
• Keep out of reach of children and pets.
• Dispose of sharps and unused injectable medication according to local regulations (pharmacy take‑back, hazardous waste collection, or approved sharps containers).

Final notes and precautions

• Legal/regulatory status: drostanolone propionate is controlled in many countries. Prescribing, possession, and distribution are regulated; verify local laws and approvals.
• Always use under prescription and medical supervision. The information above is for educational purposes and not a prescription.
• If you (or a patient) are considering or using this drug, consult an experienced clinician for individualized risk assessment, monitoring plan, and management of adverse effects.

1. Description — Clinical summary

• Generic name: drostanolone propionate (commonly marketed as “Masteron” in anabolic‑steroid contexts). The product described as “Mast P 100 mg/mL” indicates drostanolone propionate formulated at 100 mg per mL, usually as an oil-based intramuscular preparation.
• Class: synthetic anabolic–androgenic steroid (AAS), 2α‑methyl derivative of dihydrotestosterone (DHT).
• Intended/recognized uses: historically used as an androgenic/anabolic agent and (in the past) as part of therapy for certain breast cancers. In contemporary clinical practice it is rarely used and is most commonly encountered in non‑medical contexts (athletic/performance use). It is a controlled substance in many jurisdictions and should only be used under a licensed prescriber’s supervision.
• Formulation and route: oil solution for intramuscular (IM) injection. Propionate ester confers a relatively short depot half‑life compared with longer esters (e.g., enanthate).

2. How does masteron‑propionate work? — Mechanism of action

• Drostanolone is a DHT‑derived androgen that acts primarily as a selective androgen receptor (AR) agonist. It binds ARs in skeletal muscle, bone and other tissues, producing anabolic (protein‑sparing, nitrogen‑retaining) and androgenic effects.
• It is a non‑aromatizing steroid: it does not convert to estrogens by aromatase. As a result, it does not produce estrogen‑mediated effects (water retention, classical gynecomastia) to the same extent as aromatizable androgens. This property contributes to a “hardening” or anti‑water retention profile sought in some body composition contexts.
• Because it is a DHT derivative, it has relatively strong androgenic effects in tissues sensitive to DHT (skin, hair follicles, prostate), and it can suppress the hypothalamic–pituitary–gonadal (HPG) axis, leading to decreased endogenous testosterone production.
• The propionate ester affects pharmacokinetics (shorter duration of release); the active drostanolone is released after ester hydrolysis.

3. Dosage — medical and contextual guidance

Important safety note: drostanolone propionate is a prescription medication in jurisdictions where it is regulated. It should only be used when prescribed by a qualified clinician and under medical supervision. The following is informational only.

• Product concentration: “Mast P 100 mg/mL” indicates 100 mg drostanolone propionate per mL of injectable solution.
• Medical/approved use:
  • There is limited contemporary clinical use; where used historically for oncologic indications, dosing was determined by a clinician and individualized by indication, patient sex, comorbidity and response.
  • If prescribed, follow the exact dose, frequency and duration ordered by the treating physician and the product’s prescribing information.
• Non‑medical/off‑label use (informational only; not a recommendation):
  • Drostanolone propionate is often reported in non‑medical literature (athletic/bodybuilding) because of its short ester and perceived favorable aesthetic effects. Publicly available reports describe a wide range of dosing patterns. Use without prescription carries legal and substantial health risks.
  • Because of its short ester, users in non‑medical contexts often cite relatively frequent injections to maintain stable blood levels. However, discussing specific non‑prescribed regimens can facilitate misuse and is not medically advised.
• Monitoring and duration:
  • Any therapeutic use should include baseline and periodic monitoring: complete blood count (CBC; hematocrit), liver function tests (LFTs), fasting lipid profile, serum testosterone (and other relevant hormones), blood pressure, and prostate screening (PSA) in men as clinically indicated.
  • Duration of therapy, dose adjustments and course cessation should be managed by a clinician. Abrupt discontinuation after prolonged use can result in symptomatic hypogonadism; endocrine follow‑up is important.

4. Side effects — common and rare adverse effects

All potential adverse effects should be discussed with the prescribing clinician. Below are known risks associated with drostanolone/dihydrotestosterone‑derived AAS.

Common/relatively frequent

• Virilization in women: voice deepening, clitoral enlargement, menstrual irregularities, increased body/facial hair — some changes may be irreversible.
• Androgenic dermatologic effects: acne, oily skin.
• Androgenic alopecia (male pattern hair loss) in genetically susceptible individuals.
• Injection‑site reactions: pain, swelling, local irritation or abscess if aseptic technique is not used.
• Suppression of endogenous testosterone production via HPG axis suppression: testicular atrophy, decreased sperm production, infertility while using.
• Changes in lipids: reduction in HDL cholesterol and elevations in LDL cholesterol, increasing cardiovascular risk.
• Elevated hematocrit/polycythemia — increases risk of thromboembolic events.
• Mood/behavioral changes: irritability, aggression, mood swings, depressive symptoms on cessation.

Less common/serious (may require urgent medical attention)

• Cardiovascular events: increased risk of hypertension, dyslipidemia‑related atherosclerosis, myocardial infarction, stroke — risk increases with dose, duration, and preexisting cardiovascular disease.
• Hepatic effects: drostanolone is not a 17‑alpha alkylated oral steroid (so less hepatotoxic than those agents), but liver function abnormalities can still occur; cholestatic liver injury is less typical but possible.
• Prostate effects: benign prostatic hyperplasia (BPH) exacerbation, potential prostate cancer concerns in men (monitor PSA as indicated).
• Thrombotic/embolic events associated with polycythemia or lipid abnormalities.
• Allergic or hypersensitivity reactions to formulation components.

Drug interactions and contraindications

• Contraindicated in pregnancy and breastfeeding (androgens virilize female fetus/infant).
• Use with caution or avoid in patients with significant cardiac disease, uncontrolled hypertension, severe hepatic impairment, or active prostate/breast cancer unless specifically indicated and supervised.
• Can interact with anticoagulants (effects on clotting), and will affect endocrine therapies; inform all treating clinicians of use.

Emergency and overdose

• There is no specific antidote. In case of suspected overdose or severe adverse reaction (chest pain, stroke symptoms, severe shortness of breath, very rapid mood/behavioral changes), seek emergency medical care. Treatment is supportive and symptom‑directed.

5. Storage — how to store it

• Store at controlled room temperature as specified on the product label (commonly 20–25 °C / 68–77 °F) unless an alternative storage condition is stated by the manufacturer.
• Protect from light and excessive heat. Do not freeze.
• Keep the vial in its original packaging until use to protect from light.
• Inspect the solution before use (as applicable): do not use if it is discolored, contains particulate matter, or if the vial is damaged or the sterility seal is breached.
• Keep out of reach of children and pets.
• Dispose of unused or expired product and sharps (needles, syringes) in accordance with local regulations — use approved sharps containers and community disposal programs when available.
• Do not share needles or vials between individuals.

Final important notes

• Drostanolone propionate is a prescription, controlled substance in many countries. Use should be limited to medically justified indications and always supervised by a qualified healthcare professional.
• If you have specific clinical questions (e.g., about prescription dosing for a diagnosed condition, monitoring parameters for a prescribed course, or management of side effects), consult the prescribing clinician, an endocrinologist, or a pharmacist.